Limited ANDA Overlap With Ivax Creates Strong Position For Part D Benefit, Teva Says
This article was originally published in The Pink Sheet Daily
Executive Summary
There is "substantial non-overlap" between Teva's and Ivax' abbreviated new drug applications, Teva North America CEO George Barrett said